Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide 50 mg for weight management in overweight or obese adults
CTR20231053Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Overweight, obesity, type 2 diabetes mellitus (T2DM) and 4 more comparing Oral semaglutide 50 mg with Placebo (2 arms). Primary endpoints: Relative change in body weight from baseline to end of treatment and Proportion of participants with ≥5% weight loss. Started Apr 2023; status: completed.
02
Drugs
03
Conditions
Overweightobesitytype 2 diabetes mellitus (T2DM)hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on CTR20231053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231053.